Profile data is unavailable for this security.
About the company
RTW Biotech Opportunities Ltd is a Guernsey-based company focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. The Company invests in companies developing therapies and technologies that can significantly improve patients' lives. The Company seeks to achieve its investment objective by leveraging the Investment Manager's data-driven pipeline of assets to invest in life sciences companies across various therapeutic categories and product types (including genetic medicines, biologics, traditional modalities, such as small molecule pharmaceuticals and antibodies, and medical devices). It intends to create a diversified portfolio of investments across a range of businesses, each pursuing the development of superior pharmacological or medical therapeutic assets to enhance the quality of life and/or extend patient life. The Company's portfolio is managed by RTW Investments, LP.
- Revenue in USD (TTM)35.11m
- Net income in USD-92.38m
- Incorporated2019
- Employees0.00
- LocationRTW Biotech Opportunities Ltd1st Floor, Royal Chambers,, St Julian's Avenue,PO Box 650SAINT PETER PORT GY1 3JXGuernseyGGY
- Phone+44 1 481742642
- Websitehttps://www.rtwfunds.com/rtw-biotech-opportunities-ltd/
Profile
| Management group(s) | RTW Investments, LP |
|---|---|
| AIC sector | Biotechnology & Healthcare |
| ISIN | GG00BKTRRM22 |
| Launch date | 29 Oct 2019 |
| Share type | Ordinary Share |
| Structure | Investment Trust |
| Base currency | USD |
Objective
The Company seeks to achieve positive absolute performance and superior long-term capital appreciation, with a focus on forming, building, and supporting world-class life sciences, biopharmaceutical and medical technology companies. It intends to create a diversified portfolio of investments across a range of businesses, each pursuing the development of superior pharmacological or medical therapeutic assets to enhance the quality of life and/or extend patient life.
Managed by
| Naveen Yalamanchi, Roderick Wong, Woody Stileman, Oliver Kenyon |
|---|
Management & contract fees
An annual management fee of 1.25% of the NAV. If the compounded NAV return exceeds 8% p.a., the manager will be entitled to a performance fee of 20%.
Peer analysis
| Company | Revenue (TTM) | Net income (TTM) |
|---|---|---|
| Foresight Group Holdings Ltd | 220.97m | 53.07m |
| Chrysalis Investments Ltd | 185.39m | 164.00m |
| JPmorgan Claverhouse Investment Trst PLC | 79.08m | 72.92m |
| Henderson Far East Income Ltd | 76.65m | 61.41m |
| JPMorgan Emerging Markets Dvdnd Incm PLC | 83.64m | 73.11m |
| Blackrock Throgmorton Trust PLC | -53.67m | -55.96m |
| RTW Biotech Opportunities Ltd | 35.11m | -92.38m |
| IP Group Plc | 95.30m | -190.73m |
| Octopus Apollo VCT PLC | 67.18m | 38.69m |
| Fidelity Emerging Markets Ltd | 162.21m | 127.03m |
| Utilico Emerging Markets Trust PLC | 83.79m | 67.46m |
| Henderson Smaller Companies Inv Trst PLC | 16.08m | 7.48m |
| Pantheon Infrastructure PLC | 96.75m | 82.39m |
| Aberdeen Asia Focus PLC | 133.50m | 122.43m |
| SDCL Efficiency Income Trust PLC | 65.62m | 49.96m |
| Blackrock Greater Eurp Invstmnt Trst PLC | -44.43m | -54.72m |
